Background A new variant of SARS-CoV-2, B.1.1.7, emerged as the dominant cause of
COVID-19 disease in the UK from November, 2020. We report a post-hoc analysis of the efficacy …

The effectiveness of the BNT162b2 and ChAdOx1 vaccines against new severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2) infections requires continuous re-evaluation, …

Background Decisions about the continued need for control measures to contain the spread
of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) rely on accurate and up-…

Tracking the Emergence of SARS-CoV-2 Alpha Variant in the United Kingdom | NEJM Skip to
main content NEJM Group Follow Us Facebook Twitter Instagram YouTube LinkedIn Prepare …

Background: Information on SARS-CoV-2 in representative community surveillance is limited,
particularly cycle threshold (Ct) values (a proxy for viral load). Methods: We included all …

Background A new variant of SARS-CoV-2, B.1.1.7/VOC202012/01, was identified in the UK
in December-2020. Direct estimates of its potential to enhance transmission are limited. …

The effectiveness of BNT162b2, ChAdOx1, and mRNA-1273 vaccines against new SARS-CoV-2
infections requires continuous re-evaluation, given the increasingly dominant Delta …

Enhanced community surveillance is a key pillar of the public health response to coronavirus
disease 2019 (COVID-19). Asymptomatic carriage of severe acute respiratory syndrome …

Background Information on COVID-19 in representative community surveillance is limited,
particularly regarding cycle threshold (Ct) values (a proxy for SARS-CoV-2 viral load) and …

Targeted deletion of Raptor, a component of mechanistic target of rapamycin complex 1 (mTORC1),
reveals an essential role for mTORC1 in initiation/maintenance of leukemia in a CLL …